News
Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...
President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking ...
White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...
Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...
House tax bill includes PBM reforms, spread pricing restrictions & orphan drug negotiation changes, with Rep. Guthrie leading ...
Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be 'reassessed.' ...
FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.
Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology
Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...
New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results